Financial Reports

Photo
25.07.2023 • News

Bayer Lowers its Targets for the Year 2023

Bayer adjusted its full-year outlook for 2023 downward, mainly due to a significant further decline in sales of glyphosate-based products. The group has thus joined the ranks of chemical companies that have cut their annual targets in recent days and weeks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.